Skip to content

Relmada Therapeutics, Inc. RLMD Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

Merck & Co. logo
Merck & Co.MRK
$275M+10.4%
Replimune Group logo
Replimune GroupREPL
$12.76M-38.4%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$16.96M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s common stock shares outstanding?
Relmada Therapeutics, Inc. (RLMD) reported common stock shares outstanding of $37.92M in Q1 2026.
What does common stock shares outstanding mean?
This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.